Iteration of Tumor Organoids in Drug Development: Simplification and Integration

Area of Science:

• Oncology
• Biotechnology
• Drug Discovery

Background:

• Tumor complexity and heterogeneity present significant challenges for developing effective cancer therapeutics.
• Organoids, 3D in vitro models, are crucial for predicting treatment responses and advancing precision oncology.
• Patient-derived organoids correlate with clinical outcomes, bridging the gap between 2D cultures and in vivo models.

Purpose of the Study:

• To review the challenges and advancements in utilizing tumor organoids for drug screening.
• To highlight the "Organoid plus and minus" framework for improving organoid-based screening.
• To discuss the integration of emerging technologies for enhanced organoid reliability and scalability.

Main Methods:

• Review of current literature on tumor organoid technology and its applications in oncology.
• Analysis of limitations in current organoid models, including variability and microenvironmental simplification.
• Exploration of technological integrations such as AI, automated biomanufacturing, multi-omics, and vascularization.

Main Results:

• Organoids preserve tumor histopathology, cellular heterogeneity, and patient-specific molecular profiles.
• Limitations like inter-batch variability and simplified microenvironments hinder large-scale drug screening.
• Technological integration and culture system refinement are key to overcoming organoid limitations.

Conclusions:

• The "Organoid plus and minus" framework enhances screening accuracy, throughput, and physiological relevance.
• Convergence of multidisciplinary technologies, biobanking, and co-clinical validation is essential for future drug development.
• Organoids are poised to become central to personalized drug discovery and therapeutic optimization in oncology.